Exploring of bladder cancer immune-related genes and potential therapeutic targets based on transcriptomic data and Mendelian randomization analysis.

Background: Despite advancements in clinical treatment modalities, immune-related molecular mechanisms underlying bladder cancer remain unclear. Therefore, this study aimed to identify immune-related biomarkers and potential therapeutic targets for bladder cancer, thereby contributing to the development of novel therapeutic interventions.

Methods: By integrating data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and genome-wide association study (GWAS) databases, combined with differential expression analysis, weighted gene co-expression network analysis (WGCNA), and Mendelian randomization analysis, key immune-related genes in bladder cancer were identified.

A comparative study of mirabegron versus doxazosin in improving ureteral stent-related dysfunction.

Objective: To compare the efficacy of mirabegron and doxazosin in alleviating ureteral stent-related symptoms and sexual dysfunction.

Method: This study included 107 patients who provided informed consent and underwent transurethral ureteral lithotripsy with ureteral stent placement between January 2023 and December 2023. Patients were randomized into two groups receiving either mirabegron (50 mg/day) or doxazosin (4 mg/day).

Landscape of the immune infiltration and identification of molecular diagnostic markers associated with immune cells in patients with kidney transplantation.

Rejection seriously affects the success of kidney transplantations. However, the molecular mechanisms underlying this rejection remain unclear. The GSE21374 and GSE36059 datasets were downloaded from the Gene Expression Omnibus (GEO) database.